Literature DB >> 1997835

Effective surgical adjuvant therapy for high-risk rectal carcinoma.

J E Krook1, C G Moertel, L L Gunderson, H S Wieand, R T Collins, R W Beart, T P Kubista, M A Poon, W C Meyers, J A Mailliard.   

Abstract

BACKGROUND: Radiation therapy as an adjunct to surgery for rectal cancer has been shown to reduce local recurrence but has not improved survival. In a previous study, combined radiation and chemotherapy improved survival significantly as compared with surgery alone, but not as compared with adjuvant radiation, which many regard as standard therapy. We designed a combination regimen to optimize the contribution of chemotherapy, decrease recurrence, and improve survival as compared with adjuvant radiation alone.
METHODS: Two hundred four patients with rectal carcinoma that was either deeply invasive or metastatic to regional lymph nodes were randomly assigned to postoperative radiation alone (4500 to 5040 cGy) or to radiation plus fluorouracil, which was both preceded and followed by a cycle of systemic therapy with fluorouracil plus semustine (methyl-CCNU).
RESULTS: After a median follow-up of more than seven years, the combined therapy had reduced the recurrence of rectal cancer by 34 percent (P = 0.0016; 95 percent confidence interval, 12 to 50 percent). Initial local recurrence was reduced by 46 percent (P = 0.036; 95 percent confidence interval, 2 to 70 percent), and distant metastasis by 37 percent (P = 0.011; 95 percent confidence interval, 9 to 57 percent). In addition, combined therapy reduced the rate of cancer-related deaths by 36 percent (P = 0.0071; 95 percent confidence interval, 14 to 53 percent) and the overall death rate by 29 percent (P = 0.025; 95 percent confidence interval, 7 to 45 percent). Its acute toxic effects included nausea, vomiting, diarrhea, leukopenia, and thrombocytopenia. These effects were seldom severe. Severe, delayed treatment-related reactions, usually small-bowel obstruction requiring surgery, occurred in 6.7 percent of all patients receiving radiation, and the frequencies of these complications were comparable in both treatment groups.
CONCLUSIONS: The combination of postoperative local therapy with radiation plus fluorouracil and systemic therapy with a fluorouracil-based regimen significantly and substantively improves the results of therapy for rectal carcinoma with a poor prognosis, as compared with postoperative radiation alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997835     DOI: 10.1056/NEJM199103143241101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  276 in total

Review 1.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

3.  Chemotherapy of Colorectal Cancer.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

4.  Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer.

Authors:  Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

5.  [Principles of postoperative therapy in rectal carcinoma].

Authors:  G Folprecht; C-H Köhne
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

6.  Cancer chemotherapy and quality of life.

Authors:  M Byrne
Journal:  BMJ       Date:  1992-06-13

Review 7.  Colorectal cancer.

Authors:  R H Begent
Journal:  BMJ       Date:  1992-07-25

Review 8.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Local recurrence after rectal cancer treatment in Manitoba.

Authors:  Steven Latosinsky; Donna Turner
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

10.  Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.

Authors:  Vincenzo Formica; Michaela Benassi; Giovanna Del Vecchio Blanco; Elena Doldo; Laura Martano; Ilaria Portarena; Antonella Nardecchia; Jessica Lucchetti; Cristina Morelli; Emilia Giudice; Piero Rossi; Alessandro Anselmo; Pierpaolo Sileri; Giuseppe Sica; Augusto Orlandi; Riccardo Santoni; Mario Roselli
Journal:  Med Oncol       Date:  2018-05-02       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.